Physician profile
Patrick L Morgan
NPI 1245209733
$17,398.76
in general payments reported to CMS, 2019-2025
29 companies · $352 in 2025
The $352 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $110 · 2021: $279 · 2022: $15K · 2023: $485 · 2024: $549 · 2025: $352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,335 · Education: $50.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,334.99 |
| Education | $50.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $15,052.63 | 2019-2022 | |
| Abbvie INC. | $620.64 | 2019-2024 | |
| Sage Therapeutics, LLC | $233.59 | 2024-2025 | Zurzuvae |
| Astellas Pharma US INC | $162.76 | 2022-2025 | Veozah, Myrbetriq |
| Caldera Medical, INC | $145.06 | 2022-2024 | Desara |
| Mayne Pharma Commercial LLC | $140.82 | 2021-2025 | |
| Exeltis, USA INC. | $137.99 | 2020-2025 | Slynd |
| Intuitive Surgical, INC. | $136.51 | 2020-2023 | Da Vinci Surgical System |
| Boston Scientific Corporation | $109.21 | 2025 | General - Female Sui, Axonics |
| Daiichi Sankyo INC. | $107.61 | 2019-2024 | Injectafer |
| Agile Therapeutics, INC. | $82.97 | 2021-2024 | Twirla |
| Aspira Women'S Health INC | $63.77 | 2022 | |
| Myovant Sciences INC. | $53.53 | 2021 | |
| Organon LLC | $48.98 | 2024-2025 | Jada System |
| Axonics, INC. | $41.63 | 2023-2024 | Bulkamid, Axonics |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $37.15 | 2023-2024 | Myfembree |
| Pacira Pharmaceuticals Incorporated | $25.20 | 2023 | Exparel |
| Urovant Sciences INC | $22.35 | 2022 | |
| Sanofi Pasteur INC. | $22.31 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.97 | 2022 | |
| Octapharma USA, INC. | $19.17 | 2024 | Fibryga |
| Supernus Pharmaceuticals, INC. | $17.39 | 2025 | Qelbree |
| Duchesnay USA Incorporated | $15.60 | 2019 | |
| Roche Diagnostics Corporation | $14.92 | 2019 | |
| Shield Therapeutics INC | $14.43 | 2024 | |
| Pfizer INC. | $13.74 | 2025 | |
| Therapeuticsmd, INC. | $13.69 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.13 | 2023 | Seglentis |
| Amag Pharmaceuticals, INC. | $12.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.